|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.KR |
First Approval Date04 Nov 1996 |
/ Active, not recruitingNot Applicable Treatment patterns and clinical outcomes of Recombinant Follicle Stimulating Hormone in South Korean patients who received Controlled Ovarian Hyper-stimulation: Results from a retrospective observational chart review study
/ RecruitingNot Applicable The effect of minirin® on sleeping and voiding pattern to whom circadian rhythmic changed work-shift nurses
An Open-Label, Multi-Centre, Extension Trial, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients Requiring Androgen Ablation Therapy
This is an open-label, multi-centre single arm trial to investigate long-term safety and tolerability of degarelix in Korean patients with prostate cancer.
100 Clinical Results associated with Ferring Pharmaceuticals Korea Co., Ltd.
0 Patents (Medical) associated with Ferring Pharmaceuticals Korea Co., Ltd.
100 Deals associated with Ferring Pharmaceuticals Korea Co., Ltd.
100 Translational Medicine associated with Ferring Pharmaceuticals Korea Co., Ltd.